普洛药业(000739) - 2016 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥1,232,827,213.90, reflecting an increase of 11.50% year-on-year[8] - Net profit attributable to shareholders of the listed company was ¥58,334,521.45, up 25.10% compared to the same period last year[8] - Basic earnings per share for the reporting period was ¥0.0509, an increase of 25.06% year-on-year[8] - Net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 21.01% to ¥41,870,886.42[8] - The weighted average return on net assets was 2.29%, an increase of 0.35% compared to the previous year[8] Assets and Liabilities - Total assets at the end of the reporting period reached ¥5,467,573,649.11, an increase of 1.35% compared to the end of the previous year[8] - Net assets attributable to shareholders of the listed company increased by 4.53% to ¥2,526,156,829.11[8] - Accounts receivable increased by 34.53% to ¥925,654,360.52 from ¥688,076,238.76 due to an increase in sales[16] - Prepayments rose significantly by 113.54% to ¥83,133,122.61 from ¥38,931,194.20, indicating higher advance payments for goods[16] - Long-term payables increased by 100% to ¥72,000,000.00, reflecting funds received from a key construction fund[16] Cash Flow - The company reported a significant decrease of 99.14% in net cash flow from operating activities, totaling ¥1,878,192.36 for the year-to-date[8] - Cash flow from operating activities decreased by 99.14% to ¥1,878,192.36 from ¥219,614,502.92, primarily due to increased cash payments for goods and services[16] - Cash and cash equivalents decreased by 630.45% to -¥114,195,644.60 from an increase of ¥21,528,163.74, indicating higher cash outflows[16] - The company reported a 40.75% increase in cash flow from financing activities to ¥59,757,716.16 from ¥42,457,895.15, due to higher cash received from borrowings[16] Investment and Impairment - Investment income surged by 3166.88% to ¥17,946,044.44 from a loss of ¥585,157.03, attributed to the disposal of subsidiaries[16] - Asset impairment losses increased by 108.29% to ¥13,490,737.79 from ¥6,476,963.72, reflecting higher provisions for bad debts[16] - Fair value changes in financial assets resulted in a gain of ¥4,590,000.00, a turnaround from a loss of ¥4,857,766.57, driven by the settlement of forward foreign exchange products[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 62,110[12] - The largest shareholder, Hengdian Group Holdings Co., Ltd., held 23.52% of the shares, amounting to 269,752,252 shares[12] Corporate Governance - The company has committed to maintaining its independence and avoiding conflicts of interest as part of its ongoing corporate governance practices[17] - The company reported no non-operating fund occupation by controlling shareholders and their affiliates during the reporting period[24]